FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Pour des fins de recherche uniquement. Déclaration complète →

Bibliothèque de stacks

Sermorelin Sleep Protocol

GH Optimizationbeginner

82

synergie

82
Share
Pépétides

2

Moyenne journalière en mcg

300

Niveau

beginner

Ajouté

May 17, 2026

Aperçu

The Sermorelin Sleep Protocol leverages the natural relationship between growth hormone secretion and sleep architecture to enhance both simultaneously. Approximately 70% of daily GH secretion occurs during slow-wave (deep) sleep, and conversely, adequate GH signaling promotes deeper and more restorative sleep stages. Sermorelin is a 29-amino-acid GHRH analog that is identical to the first 29 amino acids of endogenous GHRH. It has a long clinical history, having been FDA-approved in the 1990s for pediatric GH deficiency, and has a long history of legal pharmacy compounding; it is not on the FDA Category 2 restricted-compounding list. When administered 30 minutes before bed on an empty stomach, Sermorelin amplifies the natural nocturnal GH surge that occurs approximately 60-90 minutes after sleep onset. This enhanced GH pulse deepens slow-wave sleep, which in turn promotes further GH release — creating a positive feedback loop. Low-dose Ipamorelin (100mcg) is added to amplify this pulse via ghrelin-receptor co-activation without doses high enough to cause any sleep-disrupting appetite signaling. The protocol is classified as beginner-friendly because Sermorelin has decades of clinical safety data, the doses are conservative, and the timing aligns with natural physiology rather than fighting it. Users typically report improvements in sleep quality within the first week, with deeper, less interrupted sleep and more vivid dreaming (indicating enhanced REM cycling). Over 4-8 weeks, the cumulative effect of improved nightly GH secretion manifests as better recovery, improved skin texture, modest fat reduction, and increased morning energy. This is an excellent entry point for individuals new to peptide therapy who want meaningful benefits with minimal complexity.

Protocole de dose

Sermorelin

nightly· subcutaneous

Lire plus sur Sermorelin →

200 mcg

par dose

Ipamorelin

nightly· subcutaneous

Lire plus sur Ipamorelin →

100 mcg

par dose

Objectifs & Preuves

Deep sleepGH pulseRecoveryAnti-agingREM sleep
Niveau d'évidence :Essai clinique humain

Avertissements

  • Sermorelin is not on the FDA Category 2 restricted list and has a long history of legal pharmacy compounding. Ipamorelin remains FDA Category 2 (restricted) as of July 2026. Administer 30 min before bed on empty stomach.

Comments

Sign in to join the discussion

Avertissement : Ce stack est soumis par la communauté et est destiné à des fins de recherche uniquement. Peptide Contacts ne vérifie pas la sécurité ou l'efficacité des stacks soumis. Consultez toujours un professionnel qualifié de la santé avant d'utiliser tout protocole de péptides.